Acrigen Biosciences

Recent Finacing

Seed

Recent Raise

Undisclosed

Acrigen Biosciences develops proprietary CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enable precise, safer in vivo gene editing and advance a pipeline of genetic-medicine therapeutics.

Founded 2019

California, United States

1-10

Private

acrigen.com

Highlights

Focus Areas

Biotechnology

Genetics

Life Science

Recent Investors

Financials

1

Funding round

4

Investors

Team

Upgrade to view the team

See the team members at Acrigen Biosciences.